Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 5/2016

01-10-2016 | Review

Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy

Authors: S. Aswathyraj, G. Arunkumar, E. K. Alidjinou, D. Hober

Published in: Medical Microbiology and Immunology | Issue 5/2016

Login to get access

Abstract

Hand, foot, and mouth disease (HFMD) is a contagious viral disease and mainly affects infants and young children. The main manifestations are fever, vesicular rashes on hand, feet and buttocks and ulcers in the oral mucosa. Usually, HFMD is self-limiting, but a small proportion of children may experience severe complications such as meningitis, encephalitis, acute flaccid paralysis and neurorespiratory syndrome. Historically, outbreaks of HFMD were mainly caused by two enteroviruses: the coxsackievirus A16 (CV-A16) and the enterovirus 71 (EV-A71). In the recent years, coxsackievirus A6 and coxsackievirus A10 have been widely associated with both sporadic cases and outbreaks of HFMD worldwide, particularly in India, South East Asia and Europe with an increased frequency of neurological complications as well as mortality. Currently, there is no pharmacological intervention or vaccine available for HFMD. A formalin-inactivated EV-A71 vaccine has completed clinical trial in several Asian countries. However, this vaccine cannot protect against other major emerging etiologies of HFMD such as CV-A16, CV-A6 and CV-A10. Therefore, the development of a globally representative multivalent HFMD vaccine could be the best strategy.
Literature
1.
2.
Solomon T, Lewthwaite P, Perera D et al (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778–790PubMedCrossRef
3.
King AMQ, Adams MJ, Lefkowitz EJ (2011) Virus taxonomy: classification and nomenclature of viruses. In: Ninth report of the international committee on taxonomy of viruses. Elsevier, Amsterdam
4.
Tapparel C, Siegrist F, Petty TJ, Kaiser L (2013) Picornavirus and enterovirus diversity with associated human diseases. Infect Genet Evol 14:282–293PubMedCrossRef
5.
Wang JF, Guo Y-S, Christakos G et al (2011) Hand, foot and mouth disease: spatiotemporal transmission and climate. Int J Health Geogr 10:1–10CrossRef
6.
Wu Y, Yeo A, Phoon MC et al (2010) The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 14:e1076–e1081PubMedCrossRef
7.
8.
9.
10.
Mirand A, Henquell C, Archimbaud C et al (2012) Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect 18:E110–E118PubMedCrossRef
11.
Keawcharoen J (2012) Hand, foot, and mouth disease. Thai J Vet Med 42:255–257
12.
Hubiche T, Schuffenecker I, Boralevi F et al (2014) Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J 33:e92–e98PubMedCrossRef
13.
Chen K-T, Lee T-C, Chang H-L et al (2008) Human enterovirus 71 disease: clinical features, epidemiology, virology, and management. Open Epidemiol J 1:10–16CrossRef
14.
Feder HM, Bennett N, Modlin JF (2014) Atypical hand, foot, and mouth disease: a vesiculobullous eruption caused by coxsackievirus A6. Lancet Infect Dis 14:83–86PubMedCrossRef
15.
Chang L-Y, Lin T-Y, Hsu K-H et al (1999) Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354:1682–1686PubMedCrossRef
16.
Lee DS, Lee YI, Ahn JB et al (2015) Massive pulmonary hemorrhage in enterovirus 71-infected hand, foot, and mouth disease. Korean J Pediatr 58:112–115PubMedPubMedCentralCrossRef
17.
Liu C-C, Chow Y-H, Chong P, Klein M (2014) Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine 32:6177–6182PubMedCrossRef
18.
Li L, Yin H, An Z, Feng Z (2015) Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine 33:1107–1112PubMedCrossRef
19.
Shimizu H, Nakashima K (2014) Surveillance of hand, foot, and mouth disease for a vaccine. Lancet Infect Dis 14:262–263PubMedCrossRef
20.
21.
Tan CW, Chan YF, Sim KM et al (2012) Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS One 7:e34589PubMedPubMedCentralCrossRef
22.
Seddon JH, Duff MF (1971) Hand-foot-and-mouth disease: coxsackievirus types A5, A10, and A16 infections. N Z Med J 74:368–373PubMed
23.
McMinn PC (2003) Enterovirus 71 in the Asia-Pacific region: an emerging cause of acute neurological disease in young children. Neurol J Southeast Asia 8:57–63
24.
25.
26.
27.
Gaunt E, Harvala H, Österback R et al (2015) Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. J Gen Virol 96:1067–1079PubMedPubMedCentralCrossRef
28.
Chu S-C, Wang E-T, Liu D-P (2013) A review of prevention and control for enterovirus infections in Asia. Epidemiol Bull 29:101–117
29.
Ishimaru Y, Nakano S, Yamaoka K, Takami S (1980) Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child 55:583–588PubMedPubMedCentralCrossRef
30.
McMinn PC (2012) Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2:199–205PubMedCrossRef
31.
Sabanathan S, Thwaites L, Wills B et al (2014) Enterovirus 71 related severe hand, foot and mouth disease outbreaks in South-East Asia: current situation and ongoing challenges. J Epidemiol Community Health 68:500–502PubMedPubMedCentralCrossRef
32.
33.
Merovitz L, Demers AM, Newby D, McDonald J (2000) Enterovirus 71 infections at a Canadian center. Pediatr Infect Dis J 19:755–757PubMedCrossRef
34.
Pérez-Vélez CM, Anderson MS, Robinson CC et al (2007) Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis Off Publ Infect Dis Soc Am 45:950–957CrossRef
35.
Bible JM, Iturriza-Gomara M, Megson B et al (2008) Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 46:3192–3200PubMedPubMedCentralCrossRef
36.
Brown BA, Oberste MS, Alexander JP et al (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73:9969–9975PubMedPubMedCentral
37.
38.
Bessaud M, Razafindratsimandresy R, Nougairède A et al (2014) Molecular comparison and evolutionary analyses of vp1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One 9:e90624PubMedPubMedCentralCrossRef
39.
Huang S-W, Cheng H-L, Hsieh H-Y et al (2014) Mutations in the non-structural protein region contribute to intra-genotypic evolution of enterovirus 71. J Biomed Sci 21:33PubMedPubMedCentralCrossRef
40.
Liu W, Wu S, Xiong Y et al (2014) Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in central China. PLoS One 9:e96051PubMedPubMedCentralCrossRef
41.
Chonmaitree T, Menegus MA, Schervish-Swierkosz EM, Schwalenstocker E (1981) Enterovirus 71 infection: report of an outbreak with two cases of paralysis and a review of the literature. Pediatrics 67:489–493PubMed
42.
Chumakov M, Voroshilova M, Shindarov L et al (1979) Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60:329–340PubMedCrossRef
43.
Hayward JC, Gillespie SM, Kaplan KM et al (1989) Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J 8:611–615PubMedCrossRef
44.
Ho M (2000) Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi 33:205–216PubMed
45.
46.
Melnick JL (1984) Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev Infect Dis 6:S387–S390PubMedCrossRef
47.
48.
Tan X, Huang X, Zhu S et al (2011) The persistent circulation of enterovirus 71 in People’s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 6:e25662PubMedPubMedCentralCrossRef
49.
Liu C-C, Tseng H-W, Wang S-M et al (2000) An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17:23–30PubMedCrossRef
50.
McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91–107PubMedCrossRef
51.
52.
Chen K-T, Chang H-L, Wang S-T et al (2007) Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998–2005. Pediatrics 120:e244–e252PubMedCrossRef
53.
Chong C-Y, Chan K-P, Shah VA et al (2003) Hand, foot and mouth disease in Singapore: a comparison of fatal and non-fatal cases. Acta Paediatr 92:1163–1169PubMedCrossRef
54.
55.
Liu C-C, Chou A-H, Lien S-P et al (2011) Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29:4362–4372PubMedCrossRef
56.
Xu J, Qian Y, Wang S et al (2010) EV71: an emerging infectious disease vaccine target in the far east? Vaccine 28:3516–3521PubMedCrossRef
57.
Zander A, Britton PN, Navin T et al (2014) An outbreak of enterovirus 71 infection in metropolitan Sydney: enhanced surveillance and lessons learnt. Med J Aust 201:663–666PubMedCrossRef
58.
Nagy G, Takátsy S, Kukán E et al (1982) Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 71:217–227PubMedCrossRef
59.
Fischer TK, Nielsen AY, Sydenham TV et al (2014) Emergence of enterovirus 71 C4a in Denmark, 2009–2013. Euro Surveill 19:20911PubMedCrossRef
60.
Hsiung GD, Wang JR (2000) Enterovirus infections with special reference to enterovirus 71. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi 33:1–8PubMed
61.
Sickles GM, Mutterer M, Feorino P, Plager H (1955) Recently classified types of coxsackievirus, group A. Behavior in tissue culture. Exp Biol Med 90:529–531CrossRef
62.
Mao Q, Wang Y, Yao X et al (2014) Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccines Immunother 10:360–367CrossRef
63.
64.
Harry T, Wright BHL (1963) Fatal infection in an infant associated with coxsackievirus group A, type 16. N Engl J Med 268:1041–1044CrossRef
65.
Wang C-Y, Li LuF, Wu M-H et al (2004) Fatal coxsackievirus A16 infection. Pediatr Infect Dis J 23:275–276PubMedCrossRef
66.
Xu W, Liu C, Yan L et al (2012) Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 9:1CrossRef
67.
68.
Robinson CR, Doane FW, Rhodes AJ (1958) Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957—isolation of group A coxsackievirus. Can Med Assoc J 79:615PubMedPubMedCentral
69.
Bendig JW, Fleming DM (1996) Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 6:R81–R86PubMed
70.
Ang LW, Koh BK, Chan KP et al (2009) Epidemiology and control of hand, foot and mouth disease in Singapore. Ann Acad Med Singap 38:106–112PubMed
71.
72.
Iwai M, Masaki A, Hasegawa S et al (2009) Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 62:254–259PubMed
73.
Kar BR, Dwibedi B, Kar SK (2013) An outbreak of hand, foot and mouth disease in Bhubaneswar, Odisha. Indian Pediatr 50:139–142PubMedCrossRef
74.
Puenpa J, Theamboonlers A, Korkong S et al (2011) Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008–2011. Arch Virol 156:2007–2013PubMedCrossRef
75.
Van Tu P, Thao NTT, Perera D et al (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13:1733–1741PubMedPubMedCentralCrossRef
76.
77.
Blomqvist S, Klemola P, Kaijalainen S et al (2010) Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol 48:49–54PubMedCrossRef
78.
Cabrerizo M, Tarrago D, Muñoz-Almagro C et al (2014) Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain. Clin Microbiol Infect 20:O150–O156PubMedCrossRef
79.
Lynch MD, Sears A, Cookson H, et al. (2015) Disseminated coxsackievirus A6 affecting children with atopic dermatitis. Clin Exp Dermatol 40(5):525–528PubMedCrossRef
80.
Montes M, Artieda J, Piñeiro LD et al (2013) Hand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 2011. Emerg Infect Dis 19:676PubMedCentralCrossRef
81.
Sinclair C, Gaunt E, Simmonds P et al (2014) Atypical hand, foot, and mouth disease associated with coxsackievirus A6 infection, Edinburgh, United Kingdom, January–February 2014. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 19:20745
82.
Ben-Chetrit E, Wiener-Well Y, Shulman LM et al (2014) Coxsackievirus A6-related hand foot and mouth disease: skin manifestations in a cluster of adult patients. J Clin Virol 59:201–203PubMedCrossRef
83.
84.
Gopalkrishna V, Patil PR, Patil GP, Chitambar SD (2012) Circulation of multiple enterovirus serotypes causing hand, foot and mouth disease in India. J Med Microbiol 61:420–425PubMedCrossRef
85.
Han J-F, Xu S, Zhang Y et al (2014) Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013. J Infect 3:303–305CrossRef
86.
Hongyan G, Chengjie M, Qiaozhi Y et al (2014) Hand, foot and mouth disease caused by coxsackievirus A6, Beijing, 2013. Pediatr Infect Dis J 33:1302–1303PubMedCrossRef
87.
Lo S-H, Huang Y-C, Huang C-G et al (2011) Clinical and epidemiologic features of coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009. J Microbiol Immunol Infect 44:252–257PubMedCrossRef
88.
Wu Y, Yeo A, Phoon MC et al (2010) The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 14:e1076–e1081PubMedCrossRef
89.
Yang F, Yuan J, Wang X, et al (2014) Severe hand, foot and mouth disease and coxsackievirus A6—Shenzhen, China. Clin Infect Dis 624
90.
Zeng H, Lu J, Zheng H et al (2015) The epidemiological study of coxsackievirus A6 revealing hand, foot and mouth disease epidemic patterns in Guangdong, China. Sci Rep 5:10550PubMedPubMedCentralCrossRef
91.
Zha J, Ma Z (2015) Epidemiological and genetic analysis concerning the coxsackievirus A6 related endemic outbreak of hand-foot-mouth disease in Taizhou, China, during 2013. J Med Virol 87(12):2000–2008PubMedCrossRef
92.
Downing C, Ramirez-Fort MK, Doan HQ et al (2014) Coxsackievirus A6 associated hand, foot and mouth disease in adults: clinical presentation and review of the literature. J Clin Virol Off Publ Pan Am Soc Clin Virol 60:381–386CrossRef
93.
Fonseca MC, Sarmiento L, Resik S et al (2014) Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011–2013. Arch Virol 159:2451–2455CrossRefPubMed
94.
Hayman R, Shepherd M, Tarring C, Best E (2014) Outbreak of variant hand-foot-and-mouth disease caused by coxsackievirus A6 in Auckland, New Zealand. J Paediatr Child Health 50:751–755PubMedCrossRef
95.
Lott JP, Liu K, Landry M-L et al (2013) Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection. J Am Acad Dermatol 69:736–741PubMedCrossRef
96.
Mathes EF, Oza V, Frieden IJ et al (2013) “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 132:e149–e157PubMedPubMedCentralCrossRef
97.
Klein M, Chong P (2015) Is a multivalent hand, foot and mouth disease vaccine feasible? Hum Vaccines Immunother 11(11):2688–2704CrossRef
98.
99.
Chung W-H, Shih S-R, Chang C-F et al (2013) Clinicopathologic analysis of coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis 208:1968–1978PubMedCrossRef
100.
Chong JH, Aan MKJ (2014) An atypical dermatologic presentation of a child with hand, foot and mouth disease caused by coxsackievirus A6. Pediatr Infect Dis J 33:889PubMedCrossRef
101.
Vuorinen T, Österback R, Kuisma J, Ylipalosaari P (2014) Epididymitis caused by coxsackievirus A6 in association with hand, foot, and mouth disease. J Clin Microbiol 52:4412–4413PubMedPubMedCentralCrossRef
102.
Feng X, Guan W, Guo Y et al (2015) A novel recombinant lineage’s contribution to the outbreak of coxsackievirus A6-associated hand, foot and mouth disease in Shanghai, China, 2012–2013. Sci. Rep. 5:11700PubMedPubMedCentralCrossRef
103.
Yang Q, Ding J, Cao J et al (2015) Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J Med Virol 87:954–960PubMedCrossRef
104.
Bracho MA, González-Candelas F, Valero A et al (2011) Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. Emerg Infect Dis 17:2223–2231PubMedPubMedCentralCrossRef
105.
He Y-Q, Chen L, Xu W-B et al (2013) Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus A6- and coxsackievirus A10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J Clin Microbiol 51:3560–3566PubMedPubMedCentralCrossRef
106.
107.
Davia JL, Bel PH, Ninet VZ et al (2011) Onychomadesis outbreak in Valencia, Spain associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol 28:1–5PubMedCrossRef
108.
Chen X, Wang C, Xu L et al (2013) A laboratory evaluation of medicinal herbs used in China for the treatment of hand, foot, and mouth disease, a laboratory evaluation of medicinal herbs used in China for the treatment of hand, foot, and mouth disease. Evid-Based Complement Altern Med Evid-Based Complement Altern Med 2013:e504563
109.
Shelley WB, Hashim M, Shelley ED (1996) Acyclovir in the treatment of hand-foot-and-mouth disease. Cutis 57:232–234PubMed
110.
Chen T-C, Weng K-F, Chang S-C et al (2008) Development of antiviral agents for enteroviruses. J Antimicrob Chemother 62:1169–1173PubMedCrossRef
111.
Chiu C-H, Chu C, He C-C, Lin T-Y (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8:1671–1678PubMedCrossRef
112.
Lin Y-C, Wu C-N, Shih S-R, Ho M-S (2002) Characterization of a vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20:2485–2493PubMedCrossRef
113.
Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5:1–13CrossRef
114.
Wang M, Jiang S, Wang Y (2013) Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun 430:387–393PubMedCrossRef
115.
Wu C-N, Lin Y-C, Fann C et al (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895–904PubMedCrossRef
116.
Yu Z, Huang Z, Sao C et al (2013) Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. Arch Virol 158:1071–1077CrossRefPubMed
117.
Zhu F, Xu W, Xia J et al (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370:818–828PubMedCrossRef
118.
Zhu F-C, Meng F-Y, Li J-X et al (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl 381:2024–2032CrossRef
119.
Li R, Liu L, Mo Z et al (2014) An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 370:829–837PubMedCrossRef
120.
Hwa S-H, Lee YA, Brewoo JN et al (2013) Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine. PLoS Negl Trop Dis 7:e2538PubMedPubMedCentralCrossRef
121.
Cheng A, Fung C-P, Liu C-C et al (2013) A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31:2471–2476PubMedCrossRef
122.
123.
Yip CC, Lau SK, Lo JY et al (2013) Genetic characterization of EV71 isolates from 2004 to 2010 reveals predominance and persistent circulation of the newly proposed genotype D and recent emergence of a distinct lineage of subgenotype C2 in Hong Kong. Virol J 10:422XCrossRef
124.
Cai Y, Liu Q, Huang X et al (2013) Active immunization with a coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 31:2215–2221PubMedCrossRef
125.
Liu F, Wu X, Li L et al (2013) Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr Purif 90:104–116PubMedCrossRef
126.
Ku Z, Liu Q, Ye X et al (2014) A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 32:4296–4303PubMedCrossRef
127.
Liang Z, Wang J (2014) EV71 vaccine, an invaluable gift for children. Clin Transl Immunol 3:e28CrossRef
128.
Schuffenecker I, Henquell C, Mirand A et al (2014) New introductions of enterovirus 71 subgenogroup c4 strains, France, 2012. Emerg Infect Dis 20:1343–1346PubMedPubMedCentralCrossRef
129.
Zhang Y, Tan X, Cui A et al (2013) Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One 8:e56341PubMedPubMedCentralCrossRef
130.
Yang E, Cheng C, Zhang Y et al (2014) Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccines Immunother 10:1266–1273CrossRef
131.
Chen XP, Tan XJ, Zhang Y, Xu WB (2014) Immunoprotective effect of inactivated coxsackievirus A16 vaccine in mice. Bing Xue Bao Chin J Virol Ji Bing Xue Bao Bian Ji Wei Yuan Hui 30:226–232
132.
133.
Sun S, Jiang L, Liang Z et al (2014) Evaluation of monovalent and bivalent vaccines against lethal enterovirus 71 and coxsackievirus A16 infection in newborn mice. Hum Vaccines Immunother 10:2885–2895CrossRef
134.
Roldão A, Mellado MCM, Castilho LR, et al (2010) Virus-like particles in vaccine development. Expert Rev Vaccine 9(10):1149–1176CrossRef
135.
136.
Yamayoshi S, Iizuka S, Yamashita T et al (2012) Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 86:5686–5696PubMedPubMedCentralCrossRef
137.
Chroboczek J, Szurgot I, Szolajska E (2014) Virus-like particles as vaccine. Acta Biochim Pol 61:531–539PubMed
138.
Luo S-T, Chiang P-S, Chao A-S et al (2009) Enterovirus 71 maternal antibodies in infants. Taiwan. Emerg Infect Dis 15:581PubMedCrossRef
139.
Chong P, Liu C-C, Chow Y-H et al (2015) Review of enterovirus 71 vaccines. Clin Infect Dis 60:797–803PubMedCrossRef
140.
141.
Chen Y-J, Chang S-C, Tsao K-C et al (2012) Comparative genomic analysis of coxsackievirus A6 strains of different clinical disease entities. PLoS One 7:e52432PubMedPubMedCentralCrossRef
142.
Centers for Disease Control and Prevention (CDC) (2012) Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6-Alabama, Connecticut, California, and Nevada, November 2011–February 2012. MMWR Morb Mortal Wkly Rep 61:213
Metadata
Title
Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy
Authors
S. Aswathyraj
G. Arunkumar
E. K. Alidjinou
D. Hober
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 5/2016
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-016-0465-y

Other articles of this Issue 5/2016

Medical Microbiology and Immunology 5/2016 Go to the issue

Original Investigation

A versatile qPCR assay to quantify trypanosomatidic infections of host cells and tissues

Original Investigation

A new report of Nocardiopsis valliformis strain OT1 from alkaline Lonar crater of India and its use in synthesis of silver nanoparticles with special reference to evaluation of antibacterial activity and cytotoxicity

Original Investigation

Highly individual patterns of virus-immune IgG effector responses in humans

Original Investigation

High seroprevalence of antibodies against Kaposi’s sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population

Original Investigation

NK cells contribute to persistent airway inflammation and AHR during the later stage of RSV infection in mice

Original Investigation

Analysis of an echovirus 18 outbreak in Thuringia, Germany: insights into the molecular epidemiology and evolution of several enterovirus species B members
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits